Related coverage linked through entity extraction aliases.
Jul 31, 2026
A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.
Apr 07, 2026
Multiple therapeutic approaches targeting the APOE4 gene are advancing, including small molecule drugs, gene therapies, and repurposed medications. The APOE4 variant confers a 60% lifetime Alzheimer's risk and affects brain metabolism, increasing seizure susceptibility. Research shows blood pressure drug terazosin can reduce seizures in APOE4 models by boosting cellular energy production.
Apr 02, 2026
Genomic technologies including whole-genome sequencing and polygenic risk scores are advancing precision medicine for neurodegenerative diseases like Alzheimer's and Parkinson's. Research reveals complex gene interactions in conditions like PTEN hamartoma tumor syndrome and sex-specific metabolic signatures in Alzheimer's disease. The integration of genomics with molecular neurobiology offers potential for more accurate diagnosis and treatment.
Mar 24, 2026
New research reveals significant advances in blood-based biomarkers for Alzheimer's disease, including a pTau 217 assay showing 93% agreement with amyloid PET imaging and identification of interferon gamma as a diagnostic signal linked to genetic risk. These developments address challenges in early diagnosis and monitoring while requiring substantially less plasma than previous tests.
Feb 13, 2026
Artificial intelligence is increasingly used to analyze Alzheimer's datasets and inform drug discovery, while researchers identify promising new drug targets including the IDOL enzyme and somatostatin receptors that could lead to more affordable treatments.
